Targets › SEMA3A
1 program from 1 company in 1 trial: 1 Phase 2; Other; next expected readout Nov 2027.
Involved in the development of the olfactory system and in neuronal control of puberty. Induces the collapse and paralysis of neuronal growth cones. (UniProt, Q14563)
Open in Phaseline: the race on SEMA3A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bayer | BAY 3401016 Semaphorin 3A (Sema3A) antagonist monoclonal antibody | SEMA3A | Phase 2 | Alport Syndrome | Nov 2027 |
Alport Syndrome (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.